Adjuvant Effects of Tranexamic Acid to Chemotherapy in Ovarian Cancer Patients with Large Amount of Ascites

Eleven patients with advanced ovarian carcinoma who had large quantities of ascites during the course of previous chemotherapy were tested with intraperitoneal injections of tranexamic acid, followed by combination chemotherapy. a 4‐g dose of tranexamic acid was administered intraperitoneally every day for at least 2 weeks. Seven out of 11 patients (63.6%) showed changes from positive to negative in Papanicolaou smears of the ascitic fluid after treatment with tranexamic acid. a marked reduction of ascitic fluids was observed in 4 of 11 patients (36.4%). If 2 cases with partial reduction of ascites are included, the response rate improved to 54.5%. Median survival time after initiation of treatment with tranexamic acid was significantly longer in patients with good response to tranexamic acid than in patients with poor response. Proliferation of cells in cultures established from ovarian cancer tissue of a patient with good response to tranexamic acid was inhibited at all concentrations of tranexamic acid used in this study, in contrast to non‐inhibition of similar cells cultured from a patient with poor response, at any concentration of tranexamic acid. These results suggest that treatment with tranexamic acid suppresses malignant cells in the ascites, followed by reduction of ascites themselves, and an improvement in the response rate to subsequent chemotherapy.

[1]  C. Tropé,et al.  Treatment of advanced breast cancer with chemotherapeutics and inhibition of coagulation and fibrinolysis. , 2009, Acta medica Scandinavica.

[2]  K. Kato,et al.  Characterization of an established cell line from human immature teratoma of the ovary and effects of retinoic acid on cell proliferation. , 1984, Cancer research.

[3]  C. Cohen,et al.  Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation). , 1983, American journal of obstetrics and gynecology.

[4]  J. Johnsson,et al.  Tranexamic Acid for the Treatment of Advanced Ovarian Carcinoma , 1983, Acta obstetricia et gynecologica Scandinavica.

[5]  R. Parmley,et al.  Inhibitory effect of L-homoarginine on murine osteosarcoma cell proliferation. , 1982, Cancer research.

[6]  L. Burnett,et al.  Advanced Ovarian Cancer: Brief Intensive Combination Chemotherapy and Second-Look Operation , 1981, Obstetrics and gynecology.

[7]  M. Yoshida,et al.  Treatment of Advanced Ovarian Cancer with Fibrinolytic Inhibitor (Tranexamic Acid) , 1980, Acta obstetricia et gynecologica Scandinavica.

[8]  Smith Jp,et al.  Diagnosis and staging of ovarian carcinoma. , 1975 .

[9]  B. Åstedt,et al.  Coagulative and fibrinolytic properties of ascitic fluid associated with ovarian tumors , 1975, Cancer.

[10]  H. Kottmeier.  Editorials: OVARIAN CANCER WITH SPECIAL REGARD TO RADIOTHERAPY , 1971 .

[11]  Woodruff Jd,et al.  The role of chemotherapy in the treatment of primary ovarian malignancy. , 1969, Obstetrical & gynecological survey.

[12]  W. Bale,et al.  Research directed toward the use of I-131 labeled fibrinogen and antibody to fibrin in the localization and treatment of tumors. , 1962, UR [reports]. U.S. Atomic Energy Commission.

[13]  Salvatore Ca,et al.  [Carcinoma of the ovary]. , 1960, Anais brasileiros de ginecologia.

[14]  J. Smith,et al.  Diagnosis and staging of ovarian carcinoma. , 1975, Seminars in oncology.

[15]  H. Kottmeier.  Ovarian cancer with special regard to radiotherapy. , 1971, The American journal of roentgenology, radium therapy, and nuclear medicine.